Fig. 3From: Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutationEP300-R1627W mutation impairs EP300 transactivation activity on both the p21 and p16 promoters. A, B Luciferase assays show that EP300-R1627W mutation impairs EP300 transactivation activity on both the p21 and p16 promoters in T24 and TCC-SUP. The bar graph shows results as relative activity compared to the control activity. C, D mRNA and protein expression of p21 and p16 after transfection of EP300-wt and EP300-R1627W plasmids in T24-EP300kd cells and TCC-SUP-EP300kd cells, respectivelyBack to article page